Smith & Nephew (SNN) Completes Acquisition of Nucryst Pharmaceuticals (NCST) Assets
The Advanced Wound Management division of Smith & Nephew plc (NYSE: SNN) have completed the acquisition of substantially all of the assets of Nucryst Pharmaceuticals (Nasdaq: NCST). The acquisition includes the manufacturing assets from Nucryst's Fort Saskatchewan, Canada operations and the intellectual property estate.
Since 2001, Smith & Nephew has held exclusive license for the sale of the ACTICOAT™ dressing portfolio, manufactured at the Ft. Saskatchewan site. This acquisition gives Advanced Wound Management full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in ACTICOAT, which is the second largest brand in the Smith & Nephew Advanced Wound Management product portfolio.
[SM]
Since 2001, Smith & Nephew has held exclusive license for the sale of the ACTICOAT™ dressing portfolio, manufactured at the Ft. Saskatchewan site. This acquisition gives Advanced Wound Management full control over all the intellectual property rights, manufacturing and assets relating to the nanocrystalline silver technology that is incorporated in ACTICOAT, which is the second largest brand in the Smith & Nephew Advanced Wound Management product portfolio.
[SM]
You May Also Be Interested In
- Syngenta (SYT) settles atrazine litigation; will pay $105M in deal
- Euroseas (ESEA) commences 13.9M rights offering
- IntercontinentalExchange (ICE) says daily crude volume hits record in May
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
